Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107717 | 0.96 | CYP2C9 (0.49) | GCKPTGS2CYP2C9 | |
| SCHEMBL12742979 | 0.91 | PTGS2 (0.46) | GCKPTGS2KCNH2CYP2C9USP2 | |
| SCHEMBL1097572 | 0.91 | CA12 (0.51) | GCKPTGS2KCNH2CYP2C9USP2 | |
| SCHEMBL2668846 | 0.91 | PTGS2 (0.49) | GCKPTGS2CYP2C9USP2 | |
| SCHEMBL1107599 | 0.91 | GCK (0.61) | GCKKCNH2 | |
| SCHEMBL1107727 | 0.90 | NOTUM (0.47) | GCKPTGS2KCNH2CYP2C9USP2 | |
| SCHEMBL3603132 | 0.89 | GCK (0.48) | GCKPTGS2KCNH2 | |
| SCHEMBL2651431 | 0.88 | GCK (0.53) | GCKKCNH2 | |
| SCHEMBL1107721 | 0.88 | GCK (0.55) | GCKKCNH2 | |
| SCHEMBL1107697 | 0.87 | GCK (0.57) | GCKPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173717-B1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL MYERS SQUIBB CO (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8273777-B2 | Glucokinase activators and methods of using same | BRISTOL-MEYER SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273777-B2 | Glucokinase activators and methods of using same | BRISTOL-MEYER SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100324071-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-23 | — | — | US | disclosed |
| US-20100324071-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-23 | — | — | US | disclosed |
| US-7812048-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812048-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| WO-2009018065-A2 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-29 | — | — | US | disclosed |
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-29 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | GCK 3/4885PTGS2 3795/4885KCNH2 921/4885 |
| US-20100324071-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, HK1 | GCK 2/4885PTGS2 3643/4885KCNH2 413/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885PTGS2 3837/4885KCNH2 716/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885PTGS2 3999/4885KCNH2 634/4885 |
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, HK1 | GCK 2/4885PTGS2 3643/4885KCNH2 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.